Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYH33 in recurrent ovarian clear cell carcinoma with PIK3CA mutations
NCT05043922Phase 2Active, not recruiting
- Sponsor
- Haihe
- Start
- Oct 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of risovalisib mesylate in ovarian clear cell carcinoma (OCCC), fallopian tube clear cell carcinoma (FTCCC), primary peritoneal clear cell carcinoma (PPCCC), sponsored by Haihe. Started Oct 2021; status: active, not recruiting.
02
Drugs
risovalisib mesylate
03
Conditions
ovarian clear cell carcinoma (OCCC)fallopian tube clear cell carcinoma (FTCCC)primary peritoneal clear cell carcinoma (PPCCC)
Beyond the preview
Go deeper on NCT05043922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043922.